Cytosorbents (NASDAQ:CTSO) Price Target Lowered to $6.00 at B. Riley

Cytosorbents (NASDAQ:CTSOGet Rating) had its target price decreased by analysts at B. Riley from $7.00 to $6.00 in a note issued to investors on Wednesday, The Fly reports. B. Riley’s price target indicates a potential upside of 175.23% from the stock’s current price.

Separately, StockNews.com started coverage on Cytosorbents in a research report on Thursday, March 31st. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $9.67.

Shares of NASDAQ:CTSO opened at $2.18 on Wednesday. The business’s 50 day simple moving average is $3.08 and its 200-day simple moving average is $4.09. The firm has a market capitalization of $94.96 million, a price-to-earnings ratio of -3.82 and a beta of 0.49. Cytosorbents has a 12 month low of $1.89 and a 12 month high of $9.80.

Cytosorbents (NASDAQ:CTSOGet Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The medical research company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.06). Cytosorbents had a negative return on equity of 34.49% and a negative net margin of 56.90%. During the same period in the previous year, the business posted ($0.10) EPS. On average, sell-side analysts expect that Cytosorbents will post -0.64 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the company. Cowen Prime Advisors LLC increased its holdings in shares of Cytosorbents by 316.0% during the 1st quarter. Cowen Prime Advisors LLC now owns 15,600 shares of the medical research company’s stock worth $50,000 after buying an additional 11,850 shares during the last quarter. Winning Points Advisors LLC purchased a new stake in Cytosorbents during the 1st quarter worth $218,000. Walleye Capital LLC purchased a new stake in Cytosorbents during the 4th quarter worth $392,000. Barclays PLC boosted its position in Cytosorbents by 191.6% during the 4th quarter. Barclays PLC now owns 50,051 shares of the medical research company’s stock worth $210,000 after purchasing an additional 32,885 shares during the period. Finally, BlackRock Inc. boosted its position in Cytosorbents by 2.8% during the 4th quarter. BlackRock Inc. now owns 2,631,210 shares of the medical research company’s stock worth $11,024,000 after purchasing an additional 72,418 shares during the period. Institutional investors and hedge funds own 40.98% of the company’s stock.

Cytosorbents Company Profile (Get Rating)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.

Recommended Stories

The Fly logo

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.